April 18, 2026 · 10 AM – 5 PM
2026 Executive Forum
Co-hosted by E-CACS, the Asian American Entrepreneur Association (AAEA), and Fox Rothschild — an exclusive discussion on preclinical strategies, FDA compliance and regulations, and technology transfer & licensing. 101 Carnegie Center Drive, Princeton, NJ 08540.
I. Preclinical strategies
- Smarter DMPK to de-risk early programs
- Translational pharmacology and biomarker strategy
- Selection and justification of translational models
- Front-loading developability and CMC considerations
- Regulatory-informed preclinical planning
- DMPK strategies for CNS models and biomarkers
Expert panel
- Marla Weetall, PTC Therapeutics
- Aidan Smith, WuXi AppTec
- Dong Liu, Seed Therapeutics
II. Compliance & Regulations
- Navigating regulatory and compliance challenges
- Preclinical study design under increasing emphasis on translational relevance
- Preclinical implications of FDA’s push toward faster drug approvals
- AI and advanced analytics in FDA filing and review
Expert panel
- Qi Cheng, Takeda Pharmaceuticals
- Ran He, THC Lawyers
- Andrew Jiang, Aleon Pharma
III. Technology Transfer & Licensing
- Key considerations in technology transfer
- Valuation and negotiation strategies for licensing deals
- Due diligence in technology transactions
- Emerging trends in life sciences licensing
- Key points in commercialization strategies
Expert panel
- Peter Butch, Fox Rothschild
- Jan Jiang, Auson Pharma
- Jasmine Lu, MSQ Ventures
- Shawn Wang, WuXi XDC
- Willie Wu, Breakthrough Genomics
Program
Full program PDF
Download the official flyer with the registration QR code and complete agenda.